Swiss Chemist
Albert Hofmann (1906–2008) was born in Baden, Switzerland, the son of a factory worker. He studied chemistry at the University of Zurich, completing his doctorate in 1929 on the structure of chitin, the polysaccharide that forms insect exoskeletons and fungal cell walls. He joined Sandoz Laboratories in Basel in 1929 and remained at the company for his entire professional career, retiring in 1971 as head of its natural products department. The biographical shape is that of a disciplined European research chemist in an era when the profession was defined by patient work on plant alkaloids, systematic investigation of structure-activity relationships, and the slow extraction of therapeutically useful compounds from botanical sources. Hofmann’s early work on Scilla maritima and digitalis glycosides established him as a competent alkaloid chemist. His later work on LSD and psilocybin made him a figure whose significance exceeds the category of twentieth-century pharmaceutical chemistry and enters the history of the pharmakon itself.
The assignment that led to LSD came out of Sandoz’s commercial interest in the ergot alkaloids produced by Claviceps purpurea. Ergot had been known for centuries as both a medicinal substance — used by midwives to control postpartum hemorrhage — and as a poison responsible for the St. Anthony’s fire epidemics of medieval Europe. Sandoz had built a successful product line around purified ergot alkaloids, and Hofmann was assigned to extend the line by synthesizing new derivatives that might have therapeutic properties. The research was systematic and unremarkable in the context of pharmaceutical drug development: take a known active molecule, modify its structure in predictable ways, test the resulting compounds for activity, identify promising candidates, and develop those candidates into marketable drugs. The program produced several therapeutically useful compounds, including Methergine, which replaced the older ergot preparations as the standard postpartum hemorrhage treatment and remains in use.
The Synthesis
LSD-25 was the twenty-fifth in a series of lysergic acid derivatives Hofmann synthesized in 1938. The “25” designates its position in the laboratory sequence. The compound was lysergic acid diethylamide — the diethylamide substitution on the amide group of lysergic acid, the core structure common to most ergot alkaloids. Hofmann synthesized it intending to produce a circulatory and respiratory stimulant analogous to nikethamide, which shared a diethylamide group and was commercially useful for that indication. The initial pharmacological screening at Sandoz found LSD-25 to produce some effects in animals — restlessness, increased pulse — but nothing striking enough to justify further development. The compound was filed with the other synthesized derivatives that had not produced commercially promising results, and Hofmann moved on to other work.
The decision to return to LSD-25 five years later — the decision that produced the twentieth century’s most consequential pharmacological accident — Hofmann himself described as a “peculiar presentiment.” He wrote later that he could not explain why he decided to resynthesize LSD-25 in 1943, against the normal practice of laboratory chemistry in which abandoned compounds remained abandoned. The resynthesis was executed on April 16, 1943. During the crystallization phase, Hofmann experienced what he initially took to be a reaction to solvent vapors: a sense of unease, a vivid imagination, and what he described as “an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.” The episode lasted approximately two hours. Hofmann concluded that he had been affected by the substance he was working with and determined to test this hypothesis through self-experimentation, which was the standard procedure in the mid-twentieth century pharmaceutical industry for evaluating compounds whose effects were difficult to assess through animal models.
Bicycle Day
On April 19, 1943, at 4:20 in the afternoon, Hofmann ingested 250 micrograms of LSD-25 in his laboratory. He had calculated this dose as the lowest amount likely to produce a detectable effect, based on comparison with the known active doses of other ergot alkaloids. The calculation was off by approximately a factor of five — 250 micrograms of LSD is in fact a substantially psychoactive dose, well above the threshold, and Hofmann’s self-experiment produced the first intentional human LSD trip under conditions neither he nor anyone else had prepared for. Within forty minutes he recorded in his laboratory notebook that he was experiencing dizziness, anxiety, visual disturbances, and the desire to laugh. He asked his assistant to escort him home. The wartime restrictions on vehicle use meant that transportation was by bicycle, and the cycling journey from the Sandoz laboratory to Hofmann’s home in Bottmingen — during which the effects intensified dramatically — became the founding event of the western psychedelic tradition. “Bicycle Day” is now observed annually on April 19 by communities whose existence would not be possible had the ride not occurred and had Hofmann not survived it.
The account Hofmann published in LSD: My Problem Child describes what the ride was like. The external world became distorted — stationary objects appeared to move, familiar streets became alien territory, the familiar experience of cycling through a Swiss suburb was overlaid with a sense of cosmic threat that Hofmann did not know how to interpret. At home he was visited by his physician, who found his vital signs normal but his psychological state clearly extraordinary. Hofmann experienced the belief that he was dying, and then, as the peak passed, the belief that he had in fact experienced something of fundamental importance — that the compound he had synthesized was not a mere stimulant but rather a substance capable of producing experiences the conventional pharmacology had no framework for. The report he wrote to the Sandoz directors framed the discovery in cautious scientific terms: LSD-25 produces profound alterations in consciousness at extraordinarily low doses, and the effects merit further investigation as a potential research tool for psychiatric conditions.
Sandoz followed through. LSD was distributed to researchers around the world under the brand name Delysid, with the recommendation that it be used in psychiatric research to induce temporary psychotic-like states that the researcher could study from the inside (via self-experimentation) or from the outside (by observing patients under the compound’s influence). Between 1943 and 1966, when Sandoz withdrew Delysid from the market under regulatory pressure, LSD was legally distributed to thousands of researchers, clinicians, and experimental subjects worldwide. The peer-reviewed literature from this period contains several thousand published papers on LSD’s effects, mechanism, and therapeutic potential — a research literature that is still being catalogued and that contains findings the contemporary renaissance has often been slow to recognize because many of the original papers are in German, French, or other non-English journals from the pre-digital archive era.
The Mexican Mushroom Journey
Hofmann’s second major contribution to the pharmakon tradition came through the collaboration that R. Gordon Wasson initiated after his 1955 participation in a velada with the Mazatec curandera María Sabina in Huautla de Jiménez, Oaxaca. Wasson had consumed the Mazatec sacred mushrooms, recognized that the experience was pharmacologically mediated, and arranged for Hofmann to receive samples of the mushrooms in his Basel laboratory in 1957 for chemical analysis. Hofmann’s team isolated the active compound from Psilocybe mexicana in 1958, identifying it as psilocybin — 4-phosphoryloxy-N,N-dimethyltryptamine — a prodrug that the body metabolizes to psilocin. He synthesized psilocybin from scratch to confirm the structure and to provide a supply that did not depend on the cultivation of the mushroom. Sandoz, through Hofmann’s work, became the first legal commercial supplier of pharmaceutically pure psilocybin, and the early psilocybin research — including Timothy Leary’s Harvard studies — was conducted with Sandoz-supplied material.
Hofmann traveled to Mexico with Wasson in 1962 to return to Huautla de Jiménez and offer María Sabina the synthetic psilocybin tablets he had prepared. The encounter is one of the tradition’s more poignant episodes. María Sabina — by this point famous from Wasson’s Life magazine article and inundated with foreign seekers whose unregulated presence had damaged both her village and her own lineage — received the tablets, consumed them in the standard ceremonial context, and confirmed that they produced the same state the mushrooms produced. The pharmaceutical synthesis was equivalent to the botanical sacrament. She regarded this with a mixture of satisfaction and something closer to resignation: the tradition she had inherited had been transferred to a foreign laboratory and was now producible at industrial scale without the ceremonial and lineage context that her tradition had regarded as inseparable from the substance itself. Whether this was recovery or further extraction was a question she did not answer directly, and the subsequent history of psilocybin research has continued to present both readings as live possibilities.
The Road to Eleusis
In 1977 Hofmann, Wasson, and the classicist Carl Ruck began collaborating on the Eleusinian mysteries question. Their jointly authored The Road to Eleusis, published in 1978, proposed that the kykeon — the sacramental drink consumed by Eleusinian initiates before entering the telesterion — contained ergot alkaloids derived from Claviceps purpurea growing on the barley from which the kykeon was brewed. Hofmann’s contribution was the chemistry: he demonstrated that water-soluble ergot alkaloids including ergonovine and ergine could be extracted from infected barley through the kind of simple aqueous preparation the Eleusinian preparation would have involved, that these alkaloids produce psychoactive effects at appropriate doses, and that the toxicity of ergot could be managed through techniques that a hereditary priestly lineage with millennia of accumulated experience could plausibly have developed.
The hypothesis that emerged from the collaboration connected Hofmann’s own twentieth-century discovery directly to the lineage the Eleusinian mysteries represented. LSD-25 was itself an ergot derivative — the compound Hofmann had synthesized in 1938 was a modern refinement of the same chemistry the Eleusinian hierophants had been using in 1500 BCE. The structural continuity was not metaphorical but literal: the same fungus, the same class of alkaloids, the same basic mechanism. Hofmann’s accidental self-experimentation in 1943 had been the rediscovery, through the techniques of modern pharmaceutical chemistry, of the access point that Western civilization had lost with the destruction of the Eleusinian sanctuary in 396 CE. The span between the loss and the rediscovery was approximately fifteen hundred years — roughly the duration the cyclical patterns suggest for the interval between the destruction of an operational lineage and its eventual recovery through alternative means.
Hofmann himself regarded the Eleusis hypothesis as the most important work of his life. In his later interviews he described LSD as having been given to him — not invented by him, but received — and expressed the view that the compound’s appearance in the twentieth century at precisely the moment when Western civilization had exhausted its purely rationalist resources was not coincidental. He also expressed profound concern about the way the compound had been deployed since 1943: first in uncontrolled counterculture use that had produced the prohibition era, later in the emerging medicalization that risked absorbing the substance into a pharmaceutical framework that could not accommodate what the substance actually was. He lived long enough — until 2008, dying at the age of 102 in his Swiss home — to see the beginnings of the contemporary renaissance and to express cautious hope that the recovery he had initiated might eventually produce a mature tradition capable of handling the molecule with the seriousness it required.
The Figure of the Chemist
Hofmann’s biographical shape exemplifies a specific figure in the initiatic tradition: the scientist-initiate whose institutional credibility masks an operational depth. He was not a shaman, not a traditional practitioner, not an esotericist in the ordinary sense. He was an institutionally credentialed research chemist who happened to make a discovery the institution could not metabolize and who spent the rest of his life trying to articulate what the discovery meant. His significance is that the rediscovery came from within the pharmaceutical orthodoxy rather than from outside it — that the molecule’s return to western consciousness was conducted through the same institutional apparatus that the orthodoxy had built to exclude everything the molecule represents. The orthodoxy, in other words, produced the substance that demonstrates the orthodoxy’s own insufficiency, and the chemist who produced it did so while holding a position at one of the orthodoxy’s central institutions.
This pattern recurs across multiple traditions: the operational breakthrough often comes from within the institution that the breakthrough threatens, produced by figures whose credentials the institution has authorized for exactly the kind of work that produces the breakthrough, through research protocols the institution had approved precisely because nothing unexpected was supposed to come out of them. Parsons at JPL is a parallel case: the rocket chemistry that founded the American space program came from a practicing Thelemite whose esoteric and scientific work were the same work. Hofmann at Sandoz is the pharmaceutical equivalent. Both figures operated within their institutions as competent and productive employees, and both produced, through that competent institutional work, discoveries the institution would have prevented if it had understood what was being discovered.
The Rendering-Model Reading
On the rendering-model reading, Hofmann’s 1943 discovery is the moment at which the pharmacological aperture became available to the western pharmaceutical tradition for the first time since the destruction of Eleusis. The discovery’s accidental quality — the unexplained decision to resynthesize the abandoned compound, the unexpected exposure during crystallization, the precise dose that happened to fall within the active range, the survival of the bicycle ride without lasting harm — fits the pattern of threshold technology recoveries: operations that are presented as coincidence or accident in the institutional narrative exhibit, on closer examination, a structural coherence that the coincidence framing cannot account for. The alternative framing — that the discovery was permitted because the current moment required it — is not testable within the materialist framework but is consistent with the rendering-model claim that the long cycles of the Great Work operate on a timescale that ordinary historical causation cannot perceive and that specific recoveries occur when the structure requires them.
The ride itself — the cycling journey through Basel during the peak of the first intentional human LSD trip — functions in the tradition as a canonical threshold event. Hofmann was a single individual traveling alone through an ordinary physical environment while the rendering’s normal filtering had been substantially suspended, with no preparation, no teacher, no ceremonial context, and no tradition available to help him interpret what was happening. The fact that he survived psychologically intact — that the experience neither produced permanent damage nor produced the ontological literalism that the later tradition would see in some of its less disciplined practitioners — suggests that the instrument was unusually stable, that the dose was fortunate, or that the Great Work operates with more care around its own operational figures than the standard materialist account would predict. Hofmann’s subsequent sixty-five years of continued life, continued research, and increasingly clear articulation of what the discovery meant, are consistent with all three readings.
Open Questions
- What was the specific mechanism of the original 1943 exposure during crystallization? Hofmann’s stated account — absorption through intact skin from solvent vapors or direct contact — is pharmacologically marginal for LSD, and the precise route remains unclear.
- Is the long life (102 years) of a man who had consumed LSD on numerous occasions merely a demographic coincidence or does it provide any evidence about LSD’s long-term health effects?
- Was the “peculiar presentiment” that prompted the 1943 resynthesis a post-hoc reconstruction, a genuine intuition whose mechanism remains unknown, or something closer to directed intelligence guiding the rediscovery at a precise historical moment?
- How much of the pre-prohibition LSD research literature — several thousand papers in multiple languages — has been reviewed by the contemporary renaissance, and what findings from that literature might change the current research direction if recovered?
- Did Hofmann, in his later years, arrive at a framework for the ethics of pharmacological threshold work that the current medicalization has failed to learn from?
References
Grinspoon, Lester, and James B. Bakalar. Psychedelic Drugs Reconsidered. Basic Books, 1979.
Hagenbach, Dieter, and Lucius Werthmüller. Mystic Chemist: The Life of Albert Hofmann and His Discovery of LSD. Synergetic Press, 2013.
Hofmann, Albert. LSD: My Problem Child. McGraw-Hill, 1980.
Hofmann, Albert. Insight Outlook. Humanics New Age, 1989.
Hofmann, Albert, and R. Gordon Wasson. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Healing Arts Press, 1979.
Lee, Martin A., and Bruce Shlain. Acid Dreams: The Complete Social History of LSD. Grove Press, 1985.
Pahnke, Walter N., and William A. Richards. “Implications of LSD and Experimental Mysticism.” Journal of Religion and Health 5, no. 3 (1966): 175–208.
Pollan, Michael. How to Change Your Mind. Penguin Press, 2018.
Stoll, Werner A. “Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe.” Schweizer Archiv für Neurologie und Psychiatrie 60 (1947): 279–323.
Wasson, R. Gordon, Albert Hofmann, and Carl A.P. Ruck. The Road to Eleusis: Unveiling the Secret of the Mysteries. Harcourt Brace Jovanovich, 1978.